PubHawk
February 2023 PMID 36860652

Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer.

Channing J Paller, Lin Wang, Wei Fu, Rajendra Kumar, Jennifer N Durham, Nilofer S Azad, Daniel A Laheru, Ilene Browner, Sushant K Kachhap, Kavya Boyapati, Thomas Odeny, Deborah K Armstrong, Christian F Meyer, Stephanie Gaillard, Julie R Brahmer

Full text PDF Download social card

Mentions

102
Peak: 19 in Feb 2023
across 4 sources since Feb 2023

Extended reach

261,162
potential audience

Total likes

464

Video views

12,174

Mentions per month

Feb 2023 – Jan 2025

Where it's discussed

  • News74 articles
  • X / Twitter22 posts
  • YouTube3 videos
  • Blogs3 articles

AI synopsis

What people are saying

The overall tone reflects a positive outlook, emphasizing the trial's safety and promising improvements in quality of life, with mentions of leading researchers and institutions supporting its significance; phrases like 'important step' and 'advancing science' highlight both enthusiasm and recognition of its potential impact.

AgreementModerate agreement

Most discussions recognize the trial's safety and potential benefits, reflecting a general positive sentiment towards the research.

InterestHigh interest

Posts express high interest by highlighting the significance of the trial's progress and potential implications for cancer treatment.

EngagementModerate engagement

Conversations show moderate engagement through mentions of specific researchers, institutions, and implications of the trial, but lack deep critical analysis.

ImpactModerate impact

The collective tone suggests the trial may influence future research and clinical practices, though it remains in early stages.

Abstract in brief

  • This study was a phase I clinical trial testing the safety and appropriate dosage of intravenous mistletoe extract (Helixor M) in patients with advanced, hard-to-treat cancers, showing it has manageable side effects and some potential to stabilize disease and improve quality of life.
  • The maximum tolerated dose was 600 mg, with common side effects like fatigue and nausea, but no objective tumor shrinkage was observed; however, some patients experienced disease stabilization and slower increases in tumor markers.
  • The results suggest that intravenous mistletoe might be safe and could offer benefits in disease control and quality of life, indicating that further research with larger, more definitive trials is needed to confirm its effectiveness.]
Read the full abstract

Top posts

Most liked on X and Bluesky
ilyas sahin, MD
@ilyassahinMD · X

1-Faz 1 çalışmasının amacı ilaç gibi test edilen bu bitki özünün güvenliğini değerlendirmekti, ancak araştırmacılar ayrıca yaşam kalitesine ve hastalık faydasına da baktı. https://t.co/qJ9fI9AYK2

Feb 22, 2023 · 22 likes · 2 shares · 20,870 followers View post →
Jodi MacLeod
@write4wellness · X

First US Phase I Clinical Trial of Intravenous #Mistletoe Extract in Advanced #Cancer completed. Thank you, Channing Paller, MD, and team and @believebig1 for advancing #integrativeoncology science. @Integrativeonc https://t.co/uKyi6soMnY https://t.co/S2p0zvCo6V

Feb 23, 2023 · 6 likes · 2 shares · 825 followers View post →
Medical Xpress
@medical_xpress · X

Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X

Feb 22, 2023 · 4 likes · 3 shares · 173,219 followers View post →
Cancer Research Communications
@CRC_AACR · X

Phase I Trial of Intravenous Mistletoe Extract in #AdvancedCancer, by @Cpaller et al. https://t.co/09QsmZdXNp @hopkinskimmel #openaccess https://t.co/AhUdL7sNbk

Feb 20, 2023 · 3 likes · 1 share · 1,567 followers View post →
Society for Integrative Oncology
@Integrativeonc · X

The team at @hopkinskimmel, led by SIO Vice President of Advancement Channing Paller @Cpaller, completed the first phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Check out the article here ➡️https://t.co/dybq8LQE2i #integrativeonc #MistletoeTherapy

Feb 23, 2023 · 2 likes · 1 share · 3,268 followers View post →
Cancer Research Communications
@CRC_AACR · X

Just published— Phase I Trial of Intravenous Mistletoe Extract in #AdvancedCancer, by @Cpaller et al. https://t.co/8fk7erX1Ig @hopkinskimmel #openaccess https://t.co/GrQ49gfy32

Feb 9, 2023 · 2 likes · 1,567 followers View post →

All mentions

Steve K
@SteveKe61657969 · X

https://t.co/t6CYyrHggI

Oct 9, 2024 · 837 followers View post →
Facts Are Good
@Facts_R_Good · X

@MaryCol81396498 @KateShemirani What makes you think you can’t? https://t.co/qifNkKIdro

Nov 6, 2023 · 1,475 followers View post →
Dr. Paul Theriault BSc, ND, FNMI, CBC
@DrPaulND · X

A new phase 1 clinical trial of Mistletoe in Cancer was safe, and showed considerable improvement in quality of life. #Naturopathic https://t.co/fdSZf4UGqQ

Mar 16, 2023 · 1 like · 5,992 followers View post →
NP AGARWAL世界一フォローを目指しますAiming best in world.
@np_grwl · X

RT @medical_xpress: Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X

Mar 3, 2023 · 3 shares · 1,788 followers View post →
Ana Maria Lopez, MD, MPH, MACP
@anamarialopezmd · X

Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer https://t.co/NH8ZvFN3x9

Feb 24, 2023 · 1,860 followers View post →
サイエンスあれこれ
@sarekore · X

では数十年にわたり、がん治療単独または化学療法や放射線療法と組み合わせた補完医療として使用されてきましたが、臨床試験では評価されていません。ME は現在、FDAに承認されていませんが、ホメオパシー薬局方に掲載されており、統合医療クリニックで提供されています。 https://t.co/QNRNWHI9kj

Feb 24, 2023 · 923 followers View post →
Stacey
@StaceG03 · X

RT @write4wellness: First US Phase I Clinical Trial of Intravenous #Mistletoe Extract in Advanced #Cancer completed. Thank you, Channing Pa…

Feb 23, 2023 · 2 shares · 330 followers View post →
Society for Integrative Oncology
@Integrativeonc · X

RT @write4wellness: First US Phase I Clinical Trial of Intravenous #Mistletoe Extract in Advanced #Cancer completed. Thank you, Channing Pa…

Feb 23, 2023 · 2 shares · 3,268 followers View post →
Jodi MacLeod
@write4wellness · X

RT @Integrativeonc: The team at @hopkinskimmel, led by SIO Vice President of Advancement Channing Paller @Cpaller, completed the first phas…

Feb 23, 2023 · 1 share · 825 followers View post →
Jodi MacLeod
@write4wellness · X

First US Phase I Clinical Trial of Intravenous #Mistletoe Extract in Advanced #Cancer completed. Thank you, Channing Paller, MD, and team and @believebig1 for advancing #integrativeoncology science. @Integrativeonc https://t.co/uKyi6soMnY https://t.co/S2p0zvCo6V

Feb 23, 2023 · 6 likes · 2 shares · 825 followers View post →
Society for Integrative Oncology
@Integrativeonc · X

The team at @hopkinskimmel, led by SIO Vice President of Advancement Channing Paller @Cpaller, completed the first phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Check out the article here ➡️https://t.co/dybq8LQE2i #integrativeonc #MistletoeTherapy

Feb 23, 2023 · 2 likes · 1 share · 3,268 followers View post →
haber
@ilimlevebilimle · X

RT @ilyassahinMD: 1-Faz 1 çalışmasının amacı ilaç gibi test edilen bu bitki özünün güvenliğini değerlendirmekti, ancak araştırmacılar ayrıc…

Feb 22, 2023 · 2 shares · 2,091 followers View post →
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry · X

Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer https://t.co/mfAeqD4Lfp

Feb 22, 2023 · 18,506 followers View post →
Steve Dudley, M.D.
@bsdudleymd · X

Important step toward making this agent available to more USA patients. #IntegrativeOncology "Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer" . https://t.co/IBbq59krNu

Feb 22, 2023 · 292 followers View post →
Ahmet
@AhmetYl83272735 · X

RT @ilyassahinMD: 1-Faz 1 çalışmasının amacı ilaç gibi test edilen bu bitki özünün güvenliğini değerlendirmekti, ancak araştırmacılar ayrıc…

Feb 22, 2023 · 2 shares · 113 followers View post →
ilyas sahin, MD
@ilyassahinMD · X

1-Faz 1 çalışmasının amacı ilaç gibi test edilen bu bitki özünün güvenliğini değerlendirmekti, ancak araştırmacılar ayrıca yaşam kalitesine ve hastalık faydasına da baktı. https://t.co/qJ9fI9AYK2

Feb 22, 2023 · 22 likes · 2 shares · 20,870 followers View post →
Manu Gupta
@guptam108 · X

RT @medical_xpress: Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X

Feb 22, 2023 · 3 shares · 1,193 followers View post →
BELIEVE BIG
@believebig1 · X

RT @CRC_AACR: Phase I Trial of Intravenous Mistletoe Extract in #AdvancedCancer, by @Cpaller et al. https://t.co/09QsmZdXNp @hopkinskimmel…

Feb 22, 2023 · 1 share · 1,023 followers View post →
Medical Xpress
@physorg_health · X

RT @medical_xpress: Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X

Feb 22, 2023 · 3 shares · 7,100 followers View post →
Medical Xpress
@medical_xpress · X

Study of intravenous mistletoe extract to treat advanced #cancer https://t.co/coVLqnORYE https://t.co/HWRb7S5H0X

Feb 22, 2023 · 4 likes · 3 shares · 173,219 followers View post →
Cancer Research Communications
@CRC_AACR · X

Phase I Trial of Intravenous Mistletoe Extract in #AdvancedCancer, by @Cpaller et al. https://t.co/09QsmZdXNp @hopkinskimmel #openaccess https://t.co/AhUdL7sNbk

Feb 20, 2023 · 3 likes · 1 share · 1,567 followers View post →
Cancer Research Communications
@CRC_AACR · X

Just published— Phase I Trial of Intravenous Mistletoe Extract in #AdvancedCancer, by @Cpaller et al. https://t.co/8fk7erX1Ig @hopkinskimmel #openaccess https://t.co/GrQ49gfy32

Feb 9, 2023 · 2 likes · 1,567 followers View post →